Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a laboratory setting, this study reported that the n-butanol fraction of Urtica laetevirens Maxim. water extracts significantly inhibited 5α-reductase activity.

This study reported that while various treatments for frontal fibrosing alopecia showed limited effectiveness, dutasteride most effectively stabilized the condition among patients at Duke University.

Deuruxolitinib is generally safe for treating alopecia areata.

This study reported that using UVB preirradiation and anti-CD154 antibody treatment in a humanized mouse model prolonged hair follicle allograft survival and reduced immune cell infiltration without needing generalized immunosuppression.

This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.

In this study, researchers found that the efflux of calcium in root hairs of Arabidopsis thaliana, particularly through the ER-localized ACA2 and ACA7, is crucial for modulating cytoplasmic calcium signals and enabling proper root hair growth, with disruptions leading to impaired elongation.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

This study found that Undariopsis peterseniana extract may promote hair growth by activating specific cellular pathways, suggesting potential for treating alopecia.

Using powdered umbilical remnant allograft can effectively treat chronic scalp wounds resistant to traditional treatments.

This study found that patients with Bachmann-Bupp syndrome treated with DFMO showed improvements in hair growth, muscle tone, and development.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This case report describes a patient with alopecia areata treated with diphencyprone, who experienced both successful hair regrowth and later intense hair shedding, compatible with telogen effluvium, suggesting a possible link between contact dermatitis treatments and telogen effluvium onset.

Among pediatric alopecia areata patients treated with DPCP, this study reported complete hair regrowth in 8.8% and any regrowth in 61.8% after one year, with better outcomes for those with milder initial symptoms and longer treatment durations.

This study found that precision 40Hz gamma-transcranial alternating current stimulation significantly improved negative and cognitive symptoms in patients with schizophrenia compared to a sham group, suggesting promising potential for this neuromodulation technique in treating these symptoms.

This study found that overexpression of a mutated ornithine decarboxylase transgene in mice led to complete hair loss, which could be prevented or reversed with an ODC inhibitor.

This case report highlights the importance of maintaining clinical suspicion for tinea incognito in patients with central centrifugal cicatricial alopecia who do not respond to typical corticosteroid treatments, as misdiagnosis can complicate treatment.

Azathioprine may be an effective treatment for severe hair loss.

This study found that injecting nu/nu mice with aqueous dispersion of unmodified fullerene C60 significantly stimulated hair growth compared to controls, suggesting its potential as a new therapeutic approach for alopecia.

This case report suggests that topical diphenylcyclopropenone (DPCP) may be beneficial for treating both alopecia areata and verruca vulgaris, although it is not typically a first-line therapy.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This case report describes a 6 1/2-year-old girl with significant height growth and early pubic hair development.

In this study, human umbilical cord mesenchymal stem cells and their conditioned medium significantly improved symptoms in mouse models of atopic dermatitis, potentially through exosome-dependent pathways, suggesting a cell-free therapeutic strategy.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.